Bio-Rad Laboratories, Inc.
BIO
$265.26
$0.940.36%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 319.17M | -2.16B | -1.84B | -778.70M | -1.33B |
| Total Depreciation and Amortization | 156.80M | 152.60M | 151.60M | 149.60M | 148.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -67.21M | 3.16B | 2.77B | 1.45B | 2.16B |
| Change in Net Operating Assets | 125.40M | -631.20M | -620.80M | -413.00M | -636.20M |
| Cash from Operations | 534.16M | 515.26M | 455.16M | 411.96M | 346.12M |
| Capital Expenditure | -163.24M | -159.84M | -165.64M | -164.99M | -168.84M |
| Sale of Property, Plant, and Equipment | 108.00K | 108.00K | 108.00K | 253.00K | 261.00K |
| Cash Acquisitions | -216.70M | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | 2.50M | 2.50M |
| Other Investing Activities | 181.16M | 45.56M | 5.36M | 104.79M | 154.76M |
| Cash from Investing | -198.68M | -114.18M | -160.18M | -57.45M | -11.31M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -464.00K | -364.00K | -464.00K | -574.00K | -569.00K |
| Issuance of Common Stock | 17.51M | 18.01M | 19.21M | 19.63M | 19.18M |
| Repurchase of Common Stock | -343.30M | -304.20M | -207.00M | -411.62M | -341.78M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -29.98M | -29.98M | -30.58M | -600.00K | -600.00K |
| Cash from Financing | -356.23M | -316.53M | -218.83M | -393.16M | -323.77M |
| Foreign Exchange rate Adjustments | -15.29M | 4.71M | 9.21M | -7.51M | 6.23M |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | 0.00 | 52.00K | 0.00 |
| Net Change in Cash | -36.05M | 89.25M | 85.35M | -46.10M | 17.26M |